Medicine and Dentistry
Programmed Death-Ligand 1
100%
Marker
83%
Patient Selection
66%
Biological Marker
66%
Immunotherapy
33%
Lung Cancer
33%
Combination Therapy
33%
Immunohistochemistry
33%
Programmed Death 1 Receptor
33%
Cells
33%
Clinical Trial
33%
Clonal Variation
16%
Protein
16%
Homeostasis
16%
Monotherapy
16%
Treatment Response
16%
Somatics
16%
Nodular Melanoma
16%
Clear Cell Renal Cell Carcinoma
16%
T Lymphocyte Receptor
16%
Cancer Therapy
16%
Solid Malignant Neoplasm
16%
Tumor Microenvironment
16%
Receptor Protein
16%
CTLA-4
16%
Protein Ligand
16%
Patient
16%
Assay
16%
Therapeutic Procedure
16%
Comprehension
16%
Consensus
16%
T Cell
16%
INIS
patients
83%
biological markers
66%
cancer
50%
proteins
50%
clinical trials
33%
tumors
33%
therapy
33%
receptors
33%
values
33%
immunotherapy
33%
lung cells
33%
apoptosis
33%
solids
16%
balances
16%
dynamics
16%
kidneys
16%
homeostasis
16%
inhibition
16%
utilities
16%
optimization
16%
antigens
16%
ligands
16%
lymphocytes
16%
melanomas
16%
carcinomas
16%